

# Novel Drug Delivery Systems Online

29TH EDITION



Oral Drug Delivery Systems and Materials

Topical and Transdermal Drug Delivery

Parenteral and Implant Drug Delivery

Delivery of Proteins and Peptides

Transmucosal Drug Delivery

Pulmonary and Nasal Drug Delivery

Drug Delivery Pipelines Database

Drug Delivery Deals Database



# Novel Drug Delivery Systems Online

29TH EDITION

## The Series

Technology Catalysts International has followed trends and published reports on the drug delivery industry since 1982. TCI is proud to announce the 29th edition of Novel Drug Delivery Systems (NDDS). The series is focused on the most critical and up-to-date information regarding drug delivery. TCI offers these NDDS reports in a hard copy version, pdf, and an online version. The online version of the reports contains the same comprehensive information on emerging drug delivery technologies that can be found in the hard copy and pdf versions of the reports. The online database, however, offers substantial benefits, including:

- Real-time updates for each technology profile
- Hyperlinked patents and publications
- Key word searches for specific companies, technologies, and products in development
- Portability – Access NDDS online from any computer, anywhere in the world

The 29th Edition of NDDS contains information on the following:

- Oral Drug Delivery Systems and Materials
- Topical and Transdermal Drug Delivery Systems
- Parenteral and Implant Drug Delivery Systems
- Delivery of Proteins and Peptides
- Transmucosal Drug Delivery Systems
- Pulmonary and Nasal Drug Delivery Systems
- Drug Delivery Pipelines
- Drug Delivery Deals, Collaborations, and Mergers

The series includes critical and concise information, all of which has been confirmed with personal interviews.

The NDDS series contain comprehensive evaluations of emerging drug delivery technologies and strategic information on over 600 companies worldwide, many of which are new to the 29th edition. Large and small corporations from around the world are identified, and their research programs and strategic plans are appropriately assessed.

Each technology is evaluated based on an assessment of its technical content, clinical value, and strategic potential. Each profile includes: *Technology Description, Applications, Technology Offer, Patents/Publications, Development Stage, Competitive Advantage, Company Information, and Contact Information*. The Technology Offer section describes the company's interest in business collaborations including license, joint venture, or other strategic alliance.

ACTOGENIX

### ActoGeniX TopAct™ Oral Delivery Technology

**TECHNOLOGY DESCRIPTION**

TopAct™ is a proprietary delivery system that genetically engineers non-pathogenic bacteria so they become effective vehicles for the delivery of therapeutic proteins and peptides into the GI tract. This platform technology is used to create ActoGeniX™ oral capsules containing food-grade bacteria that are engineered to secrete therapeutic proteins or peptides. The company has chosen to utilize *Lactococcus lactis*, as it is widely recognized as being completely safe for human consumption. ActoGeniX delivers their therapeutic proteins or peptides locally, in close proximity to the relevant GI receptors.

In the first step, a gene encoding the desired therapeutic protein (or peptide) is inserted into the chromosome of a *Lactococcus lactis* bacterium. The technology also ensures that the bacterium is able to express the gene at sufficient levels, that the relevant protein is efficiently secreted, and that the protein folds in the appropriate three-dimensional structure required for proper biological activity. As part of the same engineering process, a gene essential for survival of the bacterium is deleted. The newly created organism becomes entirely dependent on an external source of a particular nutrient (thymidine) to survive. This containment system ensures that the newly created *Lactococcus lactis* cannot survive outside the human body, or a specifically designed culturing system, and that it dies quickly if released into the environment.

When such a newly-engineered bacterial strain of *Lactococcus* has been created in the laboratory, the next step involves its production at large scale via industrial fermentation. After fermentation, the bacteria are freeze-dried and milled as a dry powder. This powder is then formulated into capsules for oral administration. When a patient ingests an ActoGeniX capsule, it passes through the stomach and subsequently dissolves in the intestinal tract, where it will slowly release the *Lactococcus* bacteria at the site of disease receptors. Once the bacteria is released into the intestinal tract, they become metabolically active and start secreting their therapeutic or "target" protein.

**APPLICATIONS**

This oral delivery technology is being applied to the local delivery of therapeutics in the GI tract. Specifically, TopAct is primarily targeting gastrointestinal diseases such as Crohn's disease, mucositis, autoimmune, allergy, and metabolic diseases.

**TECHNOLOGY OFFER**

ActoGeniX is interested in establishing strategic collaborations for the development of proprietary products using its TopAct technology. Currently, the company is collaborating with several industrial partners worldwide to enhance its resource base and assist with the development of its therapeutic drugs. ActoGeniX also has established cooperative efforts with leading universities, research labs, and clinical centers to accelerate its R&D activities.

**PATENTS / PUBLICATIONS**

ActoGeniX possesses strong and broad intellectual property rights for the TopAct platform. VIB and Ghent University, who invented the technology, transferred their entire TopAct patent estate exclusively to ActoGeniX. Recent patents include:

EP 2 164 512 (published 24 March 2010)  
 EP 2 123 010 (published 2 December 2009)  
 EP 1 948 200 (published 30 July 2009)  
 EP 1 931 792 (published 18 June 2008)  
 EP 1 789 529 (published 30 May 2007)  
 EP 1 511 245 (published 10 March 2005)  
 WO 2010/024814 (published 1 April 2010)  
 WO 2008/153120 (published 24 December 2008)  
 WO 2008/099223 (published 31 July 2008)  
 WO 2008/084115 (published 29 May 2008)  
 WO 2006/073751 (published 19 June 2006)  
 WO 2007/128757 (published 15 November 2007)  
 WO 2007/063073 (published 7 June 2007)  
 WO 2007/039386 (published 12 April 2007)  
 WO 2007/025917 (published 8 March 2007)  
 WO 2006/010103 (published 31 December 2003)  
 WO 02/090551 (published 14 November 2002)

United States Patent Application 2010/090774 (published 1 April 2010)  
 United States Patent Application 2009/074734 (published 19 March 2009)  
 United States Patent Application 2008/274084 (published 6 November 2008)  
 United States Patent Application 2008/254014 (published 16 October 2008)

Related publications include:

Wells JM, Mercier AJ. Mucosal Delivery of Therapeutic and Prophylactic Molecules Using Lactic Acid Bacteria. *Nature Reviews Microbiology* 2008, published online March 17.

Wuytens A, Ferdinande L, Weirynck S, Rottiers P, De Vos M, Steidler L, Cuvelier C. Paracellular Entry of Interleukin-10 Producing *Lactococcus lactis* in Inflamed Intestinal Mucosa in Mice. *Inflammatory Bowel Disease* 2008, 14(4):471-9.

Frossard CP, Steidler L, Eigenmann PA. Oral Administration of an IL-10-secreting *Lactococcus lactis* Strain Prevents Food-induced IgE Sensitization. *Journal of Allergy and Clinical Immunology* 2007, 119, 952-959.

Steidler L & Rottiers P. Therapeutic Drug Delivery by Genetically Modified *Lactococcus lactis* In: *Inflammatory Bowel Disease: Genetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways*, Annals of the New York Academy of Sciences 2006, Vol. 1074, 176-186.

Termont S, Vandembroucke K, Isenhardt D, Weirynck S, Steidler L, Remaut E, Rottiers P. Intracellular Accumulation of Therapeutic Proteins *Lactococcus lactis* from Freeze-drying Damage and the Toxicity and Increases Gastric Acid Assistance. *Applied and Environmental Microbiology* 2006, 72(12), 7694-7700.

**DEVELOPMENT STAGE**

Positive efficacy data was generated in models of inflammatory bowel disease, oral/intestinal mucositis, type 1 diabetes, food allergy, and obesity. Currently, ActoGeniX has one drug in clinical trial using the TopAct technology.

ActoGeniX's lead product, AG013, is an ActoGeniX for the treatment of oral mucositis. In May 2009, the FDA approved ActoGeniX's IND application, allowing the company to initiate a Phase Ib clinical trial with AG013 in cancer patients at risk of developing oral mucositis. This clinical study is now ongoing in collaboration with 6 reputed oncology centers in the US and shall be completed in Q1 2011.

TopAct™ TNFalpha antibody (AG014) is an ActoGeniX for the oral delivery of TNFalpha antibodies for the treatment of gastrointestinal diseases, in particular IBD. AG014 has been tested positively in several preclinical models and shall be ready to go into the clinic in 2012.

ActoGeniX has obtained positive efficacy data in preclinical models for several disease areas and may elect to progress product leads either through partnership with other pharmaceutical companies, or as part of its internal portfolio. These areas include:

- Colic disease
- Autoimmune diseases, including Type 1 diabetes
- Allergy-related diseases

**COMPETITIVE ADVANTAGE**

This technology is advantageous since TopAct-based products are formulated for oral delivery, leading to greater patient acceptability and reduced cost. In addition, the local administration of peptides and proteins in the GI tract is expected to lead to safe and effective medications with limited side effects. Although the human GI system integrates multiple physiological processes, ranging from food intake to regulation of immunity, direct delivery of protein- or peptide-based therapeutics to the gut is a difficult challenge due to stability and delivery issues. The TopAct technology of ActoGeniX has been shown to provide a solution to this problem by delivering active biologics locally in the GI tract, leading to a direct and efficient effect on target receptors present in the gut.

During the entire process, the bacteria is not released into the bloodstream; instead, they release the therapeutic proteins locally in the gastrointestinal tract. This is in contrast with injectable therapeutics, which are dispersed throughout the body and can therefore have systemic side effects. When delivered into the GI tract, ActoGeniX reside for 4-8 hours. During this time, they continuously release an appropriate amount of active drug molecules. As such, they mimic the way in which natural biomolecules are released by our own cells in the body. Such natural and slow release profile is in contrast with the pharmacokinetic profile of many conventional drug products, which often show a high peak of concentration in the body upon injection, followed by a quick decline shortly thereafter.

ActoGeniX are manufactured by straightforward bacterial fermentation and lyophilization. Hence, their production process is more efficient and cost-effective than most biopharmaceuticals.

**COMPANY INFORMATION**

ActoGeniX was founded in June 2006 as a spin-off from VIB and Ghent University to develop its proprietary TopAct platform for oral delivery of biopharmaceuticals. The company is developing a diverse portfolio of therapeutic products addressing major diseases with a high medical need, including gastrointestinal (GI) diseases, autoimmune, allergy, and metabolic diseases.

The company's first financing was received in September 2006 for €11.5 million. Investors participating in this Series A financing were Biotech Fund Flanders (Belgium), Ascaco (The Netherlands), Vertheb (France), and Baskeland Fund (Belgium). In February 2007, ActoGeniX closed a Series A financing round, raising €20 million from a syndicate of leading life sciences investors. The transaction was co-led by GNR (Belgium) and LSP (Life Sciences Partners - The Netherlands). In February 2009, the company closed a new financing round of €13.3 million from the existing investors and one additional investor Biinvest (Belgium).

**CONTACT INFORMATION**

Emil Pot LLM  
 Director of Business Development  
 ActoGeniX  
 Technologiepark 4  
 Zwinaarde, Ghent 9052  
 Belgium  
 Direct Phone: +32 92 610 600  
 E-Mail: Emil.Pot@actogenix.com  
 Web Site: <http://www.actogenix.com/>

Updated: 02/04/2011  
 © 2011 Technology Catalysts International Corporation  
 Close Window

\*Actual NDDS profile online.

# Oral Drug Delivery Systems and Materials

29<sup>TH</sup> EDITION

Publication: January 2011

Cost: \$5,950

This volume is an analysis of oral drug delivery technologies, both commercialized and in development, as well as business opportunities within this particular market. The report provides an analysis of the oral drug delivery market and discusses current trends in the drug delivery industry. In addition, this volume reviews mergers and acquisitions and collaborative partnerships that took place during 2010. Examples of technologies covered in this report include: intelligent polymer delivery systems, pro-liposome systems, nanoparticle technologies, orally disintegrating tablets, films, wafers, colon-targeted delivery systems, microemulsions, and chrono-therapeutic technologies. More than 275 business opportunities are identified in this report.

## Key information and analysis presented in the report:

### Oral Drug Delivery Market Analysis

- Oral DDS Blockbuster Drugs, 2009
- Current and Future Oral DDS Market

### Oral Solid Dispersion Technologies

- Challenges Facing Poorly Soluble Formulation
- Marketed Solid Dispersion Products
- Early Stage Pipeline Products and Future of Solid Dispersion

### Pulsatile Release Technologies

- Potential Applications for Pulsatile Release Systems
- Descriptions of Types of Pulsatile Systems
- Marketed Pulsatile Release Products

### Drug Delivery Acquisitions, Mergers, and Collaborations

- Mergers and Acquisitions, 2010
- Drug Deals and Collaborations, 2010

Over 200 companies with technologies available for license and/or partnership are reviewed in the report covering the following areas.

Controlled/Sustained Release	101 Technologies
Site-Specific Delivery	26 Technologies
Fast Dissolving or Tastemasking	105 Technologies
Absorption and Bioavailability Enhancement	106 Technologies
Macromolecule and Vaccine Delivery	16 Technologies

# Topical and Transdermal Drug Delivery

29<sup>TH</sup> EDITION

Publication: January 2011

Cost: \$3,950

This volume is an analysis of current topical and transdermal drug delivery technologies and business opportunities within this market. The report provides important market data on the global topical and transdermal delivery markets. Further, this volume discusses mergers and acquisitions and collaborative partnerships that took place during 2010. The topical and transdermal drug delivery systems that are covered in this report include passive patches, topical creams and gels, active patches/devices, and sprays/roll-ons. Over 125 business opportunities are identified in this report.

## Key information and analysis presented in the report:

### Transdermal – Topical Market Analysis

- Market and Revenue Leaders
- Transdermal Development
- Late Stage Topical/Transdermal Products and Future Market

### Emulsions in Topical and Transdermal Formulations

- Summary of Emulsions in Drug Delivery
- Examples of Topical Emulsion Products
- Companies Developing Emulsion Products

### Drug Delivery Acquisitions, Mergers, and Collaborations

- Mergers and Acquisitions, 2010
- Drug Deals and Collaborations, 2010

Over 120 companies with technologies available for license and/or partnership are reviewed in the report covering the following areas.

Passive Patches	45 Technologies
Active Patches/Devices	42 Technologies
Topical Creams and Gels	58 Technologies
Sprays and Roll-Ons	29 Technologies



# Parenteral and Implant Drug Delivery Systems

29TH EDITION

Publication: January 2011  
 Cost: \$5,950

This volume analyzes current technologies and business opportunities in the field of parenteral and implantable drug delivery systems. In addition, this report also discusses the current market trends and growth potential of parenteral and implant drug delivery. Examples of the technologies covered include liposomes, nanoparticles, antibody-drug conjugates, solubilization technologies, scaffolding materials, hydrogel systems, implants, and needle-free devices. Further, this volume discusses mergers and acquisitions and collaborative partnerships that took place during 2010. More than 225 business opportunities are identified in this report.

Key information and analysis presented in the report:

## Parenteral and Implant Drug Delivery Market Analysis

- Future Growth Potential
- Sales of Parenteral and Implant Products, 2009

## Cancer Targeting Technologies

- Overview of Cancer Targeting Technologies
- Marketed Products Utilizing Parenteral Technologies
- Targeting Technologies for Cancer

## Drug Delivery Acquisitions, Mergers, and Collaborations

- Mergers and Acquisitions, 2010
- Drug Deals and Collaborations, 2010

Over 200 companies with technologies available for license and/or partnership are reviewed in the report covering the following areas.

Formulation	.87	Technologies
Needle-Free Devices	.21	Technologies
Implants	.46	Technologies
Site-Specific Targeting	.69	Technologies
Sustained Release Injection	.40	Technologies

# Delivery of Proteins and Peptides

29TH EDITION

Publication: January 2011  
 Cost: \$5,950

This volume is an assessment of current technologies and business opportunities in the field of protein and peptide drug delivery systems. In addition, this volume also discusses the current market trends and growth potential of protein and peptide drug delivery systems. Examples of the technologies covered in this report include dry powder inhalers, nanoparticles based on supercritical fluid technology, liposome delivery systems, and needle-free devices. Further, this volume discusses mergers and acquisitions and collaborative partnerships that took place during 2010. More than 230 business opportunities are identified in this report.

Key information and analysis presented in the report:

## Protein and Peptide Market Analysis

- Current Protein and Peptide Market
- Sales Data for Leading Protein and Peptide Drugs with DDS Technologies
- Growth Potential and Market Forecast for Biologics

## Nasal Delivery of Macromolecules

- Overview of Developments in Nasal Delivery Companies
- Progress Beyond Small Molecules for Local Administration
- Marketed Peptide Drugs and Vaccines Delivered Nasally

## Drug Delivery Acquisitions, Mergers, and Collaborations

- Mergers and Acquisitions, 2010
- Drug Deals and Collaborations, 2010

Over 200 companies with technologies available for license and/or partnership are reviewed in the report covering the following areas.

Injection	.67	Technologies
Needle-Free Devices	.20	Technologies
Implants	.27	Technologies
Oral Delivery	.32	Technologies
Transdermal Delivery	.25	Technologies
Transmucosal Delivery	.36	Technologies
Site-Specific Targeting	.41	Technologies
Sustained Release Injection	.32	Technologies



# Transmucosal Drug Delivery

29<sup>TH</sup> EDITION

Publication: January 2011  
 Cost: \$1,950

This volume analyzes current technologies and business opportunities in the field of transmucosal drug delivery systems, excluding the nasal mucosa. In addition, this report also discusses the current trends and growth potential of the transmucosal drug delivery market. Further, this volume discusses mergers and acquisitions and collaborative partnerships that took place during 2010. More than 80 business opportunities are identified in this report.

**Key information and analysis presented in the report:**

## *Transmucosal Drug Delivery Market Analysis*

- Buccal Delivery
- Vaginal / Rectal / Ocular Delivery
- Mucosal Delivery Market Assessment
- Drug Pipeline

## *Vaginal Drug Delivery Technologies*

- Overview of Vaginal Drug Delivery Technologies
- Ongoing Vaginal DDS Development
- Marketed Vaginal Products

## *Drug Delivery Acquisitions, Mergers, and Collaborations*

- Mergers and Acquisitions, 2010
- Drug Delivery Deals and Collaborations, 2010

Over 75 companies with technologies available for license and/or partnership are reviewed in the report covering the following areas.

Buccal .....	66 Technologies
Vaginal .....	22 Technologies
Rectal .....	5 Technologies
Ocular .....	14 Technologies

# Pulmonary and Nasal Drug Delivery

29<sup>TH</sup> EDITION

Publication: January 2011  
 Cost: \$3,950

This volume is an assessment of current technologies and business opportunities in the field of pulmonary and nasal drug delivery systems. In addition, this report also discusses the current trends and growth potential of the pulmonary and nasal drug delivery market. Further, this volume discusses mergers and acquisitions and collaborative partnerships that took place during 2010. More than 90 business opportunities are identified in this report.

**Key information and analysis presented in the report:**

## *Pulmonary and Nasal Market Analysis*

- Global Pulmonary Market Summary
- Late-Stage Pulmonary Pipeline
- Worldwide Sales of the Leading Pulmonary and Nasal Delivery Products

## *Optimizing Pulmonary Delivery Via Nanotechnology*

- Overview of Nanopharmaceuticals in Pulmonary Treatments
- Molecular Targets Tested with Nanocarrier Systems

## *Drug Delivery Acquisitions, Mergers, and Collaborations*

- Mergers and Acquisitions, 2010
- Drug Delivery Deals and Collaborations, 2010

Over 80 companies with technologies available for license and/or partnership are reviewed in the report covering the following areas.

Pulmonary Formulations .....	38 Technologies
Pulmonary Devices .....	38 Technologies
Nasal Formulations .....	27 Technologies
Nasal Devices .....	12 Technologies



# Drug Delivery Pipelines Database

Publication: Continuous Online Updates

Cost: \$4,950

The Drug Delivery Pipelines database contains information on formulations in development that use novel delivery systems. The database is well-organized, easy to use, and provides an excellent resource for individuals interested in novel drug delivery formulations in development.

This internet-accessible database is designed for easy word searching on the drug name, company name, formulation, or stage of development. The Drug Delivery Pipelines database is available as a stand-alone purchase or as part of the NDDS package. The database includes over 1800 pipeline drugs that incorporate DDS technology.

Drug / Other Names	Licensor	Licensee	Indications	Formulation	Stage	Country	Tech Profile
2-METHOXYESTRADIOL Other Names: PulmoLAR Updated: 6/28/2010	PR Pharmaceuticals, Inc.		pulmonary arterial hypertension	SR-Injection	Phase I	US	
2-NAPHTHALENE SULFONIC ACID Other Names: PRO 2000 Updated: 5/1/2009	Endo Pharmaceutical Solutions		HIV, Sexually Transmitted Diseases	Vaginal Other	Phase III	US	
4-AMINO PYRIDINE Updated: 7/8/2010	Vantion Research Laboratory, LLC		Alzheimer's disease	Oral Disintegrating Tablet	Preclinical	US	
4-AMINOSALICYLATE SODIUM Other Names: AGI-022 Updated: 7/20/2010	AGI Therapeutics Ltd.		ulcerative colitis	Oral Delayed Release	Phase II	Ireland	
4-HYDROXY-TAMOXIFEN Other Names: TamoGel™ Updated: 7/23/2010	ASCENDO Therapeutics		Cyclic breast pain, Endocrine Disorders (Gynecomastia)	Transdermal	Phase II	US, France	
AC C3001 Updated: 7/20/2010	Alfacell Corporation	Tamir Biotechnology, Inc.	gliomas	RNA/Antisense	Preclinical	US	
AC C3002 Updated: 7/20/2010	Alfacell Corporation	Tamir Biotechnology, Inc.	Non-Hodgkins Lymphoma	RNA/Antisense	Preclinical	US	
AC03636 Updated: 7/20/2010	Alfacell Corporation	Tamir Biotechnology, Inc.	Brain tumor	RNA/Antisense	Preclinical	US	
ACETAMINOPHEN; HYDROCODONE BITARTRATE Updated: 7/2/2009	KV Pharmaceutical Company		Pain, fever	Oral Disintegrating Tablet	Formulation Stage	US	
ACETAMINOPHEN Updated: 5/27/2010	TransDermal Technologies, Inc.		pain	Transdermal	Development	US	

\*Actual website view.

# Drug Delivery Deals Database

Publication: Continuous Online Updates

Cost: \$1,950

TCI has created a drug delivery deals database to assist clients in tracking the important business transactions taking place in the drug delivery industry. There were 208 drug delivery licensing deals publicly disclosed in 2010. TCI tracks and extracts the most important information regarding the deals, including royalty, milestone, and licensing payments. Each entry includes the financial information as reported. The database allows the user to search by licensee, licensor, compound, and formulation.

This is the only database of its kind devoted solely to the tracking of drug delivery deals. The database includes licensing deals dating from 1995 to the present. This database is an excellent resource for both technical and business professionals for tracking historical and recent deals. The Drug Delivery Deals database is available as a stand-alone purchase or as part of the NDDS package.

Technology Catalysts International DRUG DELIVERY DEALS	
Press Release Date:	02/03/2011
Licensor Parent:	
Licensor:	Nitto Denko Corporation
Licensee Parent:	
Licensee(s):	Avecia Biotechnology, Inc.
Product / Process:	M&A
Formulation Type:	None: Merger/Acquisition, RNA/Antisense
License Terms:	<p>Japan's leading diversified materials manufacturer, Nitto Denko, announced that it has acquired Avecia Biotechnology through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey. Nitto Denko aims to strengthen its business base in the domain of nucleic acid drugs with this acquisition, in light of the industry's great growth potential.</p> <p>With an unmatched track record in large scale manufacturing and extensive expertise across a broad range of nucleic acid APIs (active pharmaceutical ingredients), Avecia is the market leader in contract manufacturing and related services for nucleic acid drugs. This acquisition represents a significant commitment by Nitto Denko to the nucleic acid drug industry. Nitto Denko will further expand its business in this industry by leveraging the following synergies with Avecia:</p> <ol style="list-style-type: none"> <li>1. Strong complementary market positions and client relationships</li> <li>2. Combined IP and technologies, including drug delivery technologies</li> <li>3. Improved nucleic acid manufacturing efficiencies and cost of goods with Nitto Denko's proprietary solid polymer support technology</li> <li>4. Avecia's prime location and expansion possibilities to grow the service offering for the benefit of our clients</li> </ol> <p>Nitto Denko already is active in nucleic acid drug technology with its wholly owned subsidiary Nitto Denko Technica Corporation in Oceanside, California. NDT is currently expanding its technological development of the chemical synthesis of nucleic acid drugs.</p> <p>With the acquisition of Avecia, Nitto Denko will further boost its business base in this drug technology domain by leveraging the additional contract manufacturing business of nucleic acid drugs.</p>

\*Actual website view.



# TECHNOLOGY CATALYSTS INTERNATIONAL

## Novel Drug Delivery Systems Order Form

Please check the box of the report(s) that you are interested in ordering from TCI.  
 Note: All prices are U.S. dollars

Online Version	PDF Version	Report Title	Cost
		29th Edition Oral Drug Delivery Systems and Materials (January 2011)	\$5,950
		29th Edition Topical and Transdermal Drug Delivery (January 2011)	\$3,950
		29th Edition Parenteral and Implant Drug Delivery Systems (January 2011)	\$5,950
		29th Edition Delivery of Proteins and Peptides (January 2011)	\$5,950
		29th Edition Transmucosal Drug Delivery (January 2011)	\$1,950
		29th Edition Pulmonary and Nasal Drug Delivery (January 2011)	\$3,950
		Drug Delivery Pipelines Database	\$4,950
		Drug Delivery Deals Database	\$1,950

**Special Offers:** *Access to the entire series:*

	Entire Series of Novel Drug Delivery Systems Online Includes: Protein & Peptide, Parenteral and Implant, Oral, Transdermal, Transmucosal, Pulmonary and Nasal, Drug Delivery Deals and Pipelines Databases	\$25,000
--	--	----------

- No additional charge for up to 5 users for NDDS Online
- Customized portions of the reports available. Please call TCI for pricing.

We agree to limit the circulation of this report to employees of our corporation or subsidiaries and joint ventures in which our corporation holds at least a 50 percent interest.

Please fill in for all payment methods:

Name \_\_\_\_\_ Title \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Company \_\_\_\_\_

Address \_\_\_\_\_

Telephone \_\_\_\_\_ E-mail \_\_\_\_\_

**Please check form of payment. There are three easy ways to pay:**

1. Credit Card     2. Check     3. Wire Transfer

1. For credit card payment, please charge credit card:     Master Card     Visa     AMEX

Card # \_\_\_\_\_ Expiration Date: \_\_\_\_\_

Security Code (3 or 4 digit #): \_\_\_\_\_ Total Amount: \_\_\_\_\_

2. Please send your check to Technology Catalysts International 605 Park Ave., Falls Church, VA 22046

3. Wire Transfer Information:  
 Please contact TCI directly for account information.

**E-mail, Mail, Fax, or Phone your order to:**

Ajay Rastogi  
 Vice President

**Technology Catalysts International Corporation**  
 605 Park Avenue, Falls Church, VA 22046 USA  
 Telephone: (703) 531-0257 • Facsimile: (703) 237-0042  
 E-mail: arastogi@technology-catalysts.com

Upon receipt of this signed Purchase Agreement, Technology Catalysts International will invoice the purchasing company for the purchase amount, payable upon request.





## About Technology Catalysts International

Technology Catalysts International (TCI) was founded in 1979 to provide consulting services that satisfy the licensing and business research needs of the personal care, food and nutrition, and OTC healthcare industries. We specialize in technology licensing, technology assessment, and technology portfolio management. The firm is headquartered in Falls Church, Virginia, a suburb of Washington D.C. Our global network includes offices in Japan, Korea, India, Argentina, the United Kingdom, Germany, China, and Czech Republic.

Our research staff is composed of professionals with backgrounds in a variety of technical disciplines with additional expertise in international marketing, licensing, finance, and business development. The breadth of our experience assures clients of high quality, actionable information, and complete coverage on topics of interest.

TCI's core consulting services are based on continuous monitoring of global technology development. We provide consulting and technology transfer services to leading product developers and manufacturers in North and South America, Europe, and Asia. Our client base consists of small, medium, and large corporations.

## Worldwide contacts for additional information

### World Headquarters

Ajay Rastogi  
Vice President  
Technology Catalysts International Corporation  
605 Park Avenue  
Falls Church, VA 22046 USA  
Telephone: (703) 531-0257  
Facsimile: (703) 237-0042  
E-mail: [arastogi@technology-catalysts.com](mailto:arastogi@technology-catalysts.com)  
Internet: [www.technology-catalysts.com](http://www.technology-catalysts.com)

### Europe

Graham L. Crawford, MSc  
Managing Director  
Technology Catalysts International UK  
Blacksmiths  
Clifton Road  
Newton Blossomville  
Bedford MK43 8AS UK  
Telephone: +44 1234 881583  
Facsimile: +44 1234 881027  
E-mail: [gcrawford@technology-catalysts.com](mailto:gcrawford@technology-catalysts.com)

Gerhard Wallenwein, Ph.D.  
Managing Director  
Laves Chemie Consulting  
Koenigsteiner Strasse 80  
D-65812 Bad Soden, Germany  
Telephone: +49 6196 62057  
Facsimile: +49 6196 27837  
E-mail: [laveschemie@t-online.de](mailto:laveschemie@t-online.de)  
Internet: [www.laveschemie.de](http://www.laveschemie.de)

Jana Kuhnlova  
Managing Director  
Inventia s.r.o.  
Na Belidle 3  
150 00 Praha 5 - Smíchov, Czech Republic  
Telephone: +420 2 22247484  
Facsimile: +420 2 24218645  
E-mail: [kuhnlova@inventia.cz](mailto:kuhnlova@inventia.cz)  
Internet: [www.inventia.cz](http://www.inventia.cz)

Milos Hraba  
Manager NBD  
Inventia s.r.o.  
Na Belidle 3  
150 00 Praha 5 - Smíchov, Czech Republic  
Telephone: +420 2 22247484  
Facsimile: +420 2 24218645  
E-mail: [hraba@inventia.cz](mailto:hraba@inventia.cz)

### Asia

Sansei Oka  
Japanese Business Representative  
Technology Catalysts International  
4-18-11-101, Takada-Higashi  
Kohoku-Ku, Yokohama 223-0065, Japan  
Telephone: +81 45 543 5578  
E-mail: [soka@technology-catalysts.com](mailto:soka@technology-catalysts.com)

Mitsuhisa Tamura  
Senior Research Associate  
Sumika Technical Information Service Inc.  
15 Fl., Tokyo Sumitomo Twin Bldg. (East)  
27-1, Shinkawa 4-chome  
Chuo-ku, Tokyo 104-0033, Japan  
Telephone: +81 3 5543 5875  
Facsimile: +81 3 5543 5945  
E-mail: [mitsuhisa-tamura@ya.sumitomo-chem.co.jp](mailto:mitsuhisa-tamura@ya.sumitomo-chem.co.jp)  
Internet: [www.stis.co.jp](http://www.stis.co.jp)

Don Ki Kim  
President & CEO, Pharmacist  
Global Damon Pharma  
Seoul  
Korea  
Telephone: +82 2 3673-2367  
Facsimile: +82 2 3673-2369  
E-mail: [dkkim@gdp.co.kr](mailto:dkkim@gdp.co.kr)

Jaison Abraham  
General Manager  
TCI India  
Level 4, Dynasty, 'A' Wing  
Andheri-Kurla Road  
Andheri East  
Mumbai 400 069, India  
Telephone: +91-22-4030 9499  
Facsimile: +91-22-4030 9199  
Mobile: +91-98-1932 8598  
E-mail: [jabraham@technology-catalysts.com](mailto:jabraham@technology-catalysts.com)

R.K. Gupta  
Managing Director  
Industrial Development Services Pvt. Ltd.  
M-1 Kanchenjunga  
18 Barakhamba Road  
New Delhi 110 001, India  
Telephone: +91-11- 2 331 2287; 2 331 4714  
Facsimile: +91-11-23738227  
E-mail: [ids@del2.vsnl.net.in](mailto:ids@del2.vsnl.net.in)  
Internet: [www.ids-india.org](http://www.ids-india.org)

### South America

Carlos A. Massone M.D.  
President  
Qualia S.A.  
Jeronimo Salguero 2533, Piso 12 "A"  
1425, Buenos Aires, Argentina  
Telephone: +54 11 4807 3433  
Facsimile: +54 11 4807 2933  
E-mail: [carlos.massone@qualia.com.ar](mailto:carlos.massone@qualia.com.ar)  
Internet: [www.qualia.com.ar](http://www.qualia.com.ar)

Visit TCI's Website at:

[www.technology-catalysts.com](http://www.technology-catalysts.com)